Thyroid Eye Disease study: Linsitinib
Official title Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ClinicalTrials.gov ID: NCT06112340
What this study is testing
What is linsitinib?
linsitinib is an investigational medicine, taken by mouth twice daily, being studied as a potential treatment for thyroid eye disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to see if linsitinib is effective and safe for people who did not improve or whose symptoms returned after a previous trial.
- Who it's for
- People with active, moderate to severe thyroid eye disease who participated in a prior study and did not respond or had a relapse.
- What's involved
- Participants will receive two doses of linsitinib and undergo tests to check how the drug works in their body and any side effects.
- Time commitment
- The study continues until Week 24 for participants from the previous trial.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\< 2 mm reduction in proptosis in the study...
- Subject has not received any treatment for TED since Week 24 of VGN-TED-301
- people must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4]...
- Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not...
You likely can't join if
- The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
- Morgantown, West Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States; Morgantown, West Virginia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.